Page 341 - Binder2

steel, sterile corridors, and vertically integrated supply
chains.

But edible biologics rewrite that script.

Because if a life-saving therapy can be grown in a
greenhouse, processed in a clean-room ag facility, and
delivered in a capsule—then the power doesn’t reside in
a factory.
It resides in a protocol.

What Happens When the Grip Slips?

The real disruption isn’t technological. It’s structural.
And it starts to look like this:

● A biotech startup brings a product to clinical
trial—not with $500 million in venture capital, but
with $5 million, a gene construct, and an AI-
optimized plant growth system.
● A government health agency in the Global South
begins manufacturing oral insulin locally—at a
fraction of the cost of imported injectables—serving
its own population with domestic capability.
● Nonprofit research institutions develop open-
source vaccine candidates expressed in edible
crops—sharing the protocols publicly, enabling
localized production around the world.
● IP protections weaken, not because the science is
stolen, but because the value lies in biology’s
execution, not in the blueprint.

This isn’t just a new delivery format.
It’s a new power map.

339